These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 30190462)

  • 1. Co-activation of super-enhancer-driven CCAT1 by TP63 and SOX2 promotes squamous cancer progression.
    Jiang Y; Jiang YY; Xie JJ; Mayakonda A; Hazawa M; Chen L; Xiao JF; Li CQ; Huang ML; Ding LW; Sun QY; Xu L; Kanojia D; Jeitany M; Deng JW; Liao LD; Soukiasian HJ; Berman BP; Hao JJ; Xu LY; Li EM; Wang MR; Bi XG; Lin DC; Koeffler HP
    Nat Commun; 2018 Sep; 9(1):3619. PubMed ID: 30190462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Super-Enhancer-Driven Long Non-Coding RNA LINC01503, Regulated by TP63, Is Over-Expressed and Oncogenic in Squamous Cell Carcinoma.
    Xie JJ; Jiang YY; Jiang Y; Li CQ; Lim MC; An O; Mayakonda A; Ding LW; Long L; Sun C; Lin LH; Chen L; Wu JY; Wu ZY; Cao Q; Fang WK; Yang W; Soukiasian H; Meltzer SJ; Yang H; Fullwood M; Xu LY; Li EM; Lin DC; Koeffler HP
    Gastroenterology; 2018 Jun; 154(8):2137-2151.e1. PubMed ID: 29454790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TP63, SOX2, and KLF5 Establish a Core Regulatory Circuitry That Controls Epigenetic and Transcription Patterns in Esophageal Squamous Cell Carcinoma Cell Lines.
    Jiang YY; Jiang Y; Li CQ; Zhang Y; Dakle P; Kaur H; Deng JW; Lin RY; Han L; Xie JJ; Yan Y; Doan N; Zheng Y; Mayakonda A; Hazawa M; Xu L; Li Y; Aswad L; Jeitany M; Kanojia D; Guan XY; Said JW; Yang W; Fullwood MJ; Lin DC; Koeffler HP
    Gastroenterology; 2020 Oct; 159(4):1311-1327.e19. PubMed ID: 32619460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interplay and cooperation between SREBF1 and master transcription factors regulate lipid metabolism and tumor-promoting pathways in squamous cancer.
    Li LY; Yang Q; Jiang YY; Yang W; Jiang Y; Li X; Hazawa M; Zhou B; Huang GW; Xu XE; Gery S; Zhang Y; Ding LW; Ho AS; Zumsteg ZS; Wang MR; Fullwood MJ; Freedland SJ; Meltzer SJ; Xu LY; Li EM; Koeffler HP; Lin DC
    Nat Commun; 2021 Jul; 12(1):4362. PubMed ID: 34272396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SOX2 and p63 colocalize at genetic loci in squamous cell carcinomas.
    Watanabe H; Ma Q; Peng S; Adelmant G; Swain D; Song W; Fox C; Francis JM; Pedamallu CS; DeLuca DS; Brooks AN; Wang S; Que J; Rustgi AK; Wong KK; Ligon KL; Liu XS; Marto JA; Meyerson M; Bass AJ
    J Clin Invest; 2014 Apr; 124(4):1636-45. PubMed ID: 24590290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenomic Profiling Discovers Trans-lineage SOX2 Partnerships Driving Tumor Heterogeneity in Lung Squamous Cell Carcinoma.
    Sato T; Yoo S; Kong R; Sinha A; Chandramani-Shivalingappa P; Patel A; Fridrikh M; Nagano O; Masuko T; Beasley MB; Powell CA; Zhu J; Watanabe H
    Cancer Res; 2019 Dec; 79(24):6084-6100. PubMed ID: 31551362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SOX2 represses c-MYC transcription by altering the co-activator landscape of the c-MYC super-enhancer and promoter regions.
    Ormsbee Golden BD; Gonzalez DV; Yochum GS; Coulter DW; Rizzino A
    J Biol Chem; 2024 Sep; 300(9):107642. PubMed ID: 39122009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of bivalent factor DLX5 cooperates with master regulator TP63 to promote squamous cell carcinoma.
    Huang Y; Yang Q; Zheng Y; Lin L; Xu X; Xu XE; Silva TC; Hazawa M; Peng L; Cao H; Ding Y; Lu D; Berman BP; Xu LY; Li EM; Yin D
    Nucleic Acids Res; 2021 Sep; 49(16):9246-9263. PubMed ID: 34370013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NRG1 is a critical regulator of differentiation in TP63-driven squamous cell carcinoma.
    Hegde GV; de la Cruz C; Giltnane JM; Crocker L; Venkatanarayan A; Schaefer G; Dunlap D; Hoeck JD; Piskol R; Gnad F; Modrusan Z; de Sauvage FJ; Siebel CW; Jackson EL
    Elife; 2019 May; 8():. PubMed ID: 31144617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p63 and SOX2 Dictate Glucose Reliance and Metabolic Vulnerabilities in Squamous Cell Carcinomas.
    Hsieh MH; Choe JH; Gadhvi J; Kim YJ; Arguez MA; Palmer M; Gerold H; Nowak C; Do H; Mazambani S; Knighton JK; Cha M; Goodwin J; Kang MK; Jeong JY; Lee SY; Faubert B; Xuan Z; Abel ED; Scafoglio C; Shackelford DB; Minna JD; Singh PK; Shulaev V; Bleris L; Hoyt K; Kim J; Inoue M; DeBerardinis RJ; Kim TH; Kim JW
    Cell Rep; 2019 Aug; 28(7):1860-1878.e9. PubMed ID: 31412252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A predominant enhancer co-amplified with the SOX2 oncogene is necessary and sufficient for its expression in squamous cancer.
    Liu Y; Wu Z; Zhou J; Ramadurai DKA; Mortenson KL; Aguilera-Jimenez E; Yan Y; Yang X; Taylor AM; Varley KE; Gertz J; Choi PS; Cherniack AD; Chen X; Bass AJ; Bailey SD; Zhang X
    Nat Commun; 2021 Dec; 12(1):7139. PubMed ID: 34880227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IRF4-induced upregulation of lncRNA SOX2-OT promotes cell proliferation and metastasis in cholangiocarcinoma by regulating SOX2 and PI3K/AKT signaling.
    Wei CX; Wong H; Xu F; Liu Z; Ran L; Jiang RD
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8169-8178. PubMed ID: 30556855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of SOX2 induces cell apoptosis and G1/S arrest in Ewing's sarcoma through the PI3K/Akt pathway.
    Ren C; Ren T; Yang K; Wang S; Bao X; Zhang F; Guo W
    J Exp Clin Cancer Res; 2016 Mar; 35():44. PubMed ID: 26969300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TP63 links chromatin remodeling and enhancer reprogramming to epidermal differentiation and squamous cell carcinoma development.
    Yi M; Tan Y; Wang L; Cai J; Li X; Zeng Z; Xiong W; Li G; Li X; Tan P; Xiang B
    Cell Mol Life Sci; 2020 Nov; 77(21):4325-4346. PubMed ID: 32447427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reciprocal inhibition between TP63 and STAT1 regulates anti-tumor immune response through interferon-γ signaling in squamous cancer.
    Jiang Y; Zheng Y; Zhang YW; Kong S; Dong J; Wang F; Ziman B; Gery S; Hao JJ; Zhou D; Zhou J; Ho AS; Sinha UK; Chen J; Zhang S; Yin C; Wei DD; Hazawa M; Pan H; Lu Z; Wei WQ; Wang MR; Koeffler HP; Lin DC; Jiang YY
    Nat Commun; 2024 Mar; 15(1):2484. PubMed ID: 38509096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TP63-Mediated Enhancer Reprogramming Drives the Squamous Subtype of Pancreatic Ductal Adenocarcinoma.
    Somerville TDD; Xu Y; Miyabayashi K; Tiriac H; Cleary CR; Maia-Silva D; Milazzo JP; Tuveson DA; Vakoc CR
    Cell Rep; 2018 Nov; 25(7):1741-1755.e7. PubMed ID: 30428345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. lncRNA CCAT1 is a biomarker for the proliferation and drug resistance of esophageal cancer via the miR-143/PLK1/BUBR1 axis.
    Hu M; Zhang Q; Tian XH; Wang JL; Niu YX; Li G
    Mol Carcinog; 2019 Dec; 58(12):2207-2217. PubMed ID: 31544294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SOX2 antagonizes WWC1 to drive YAP1 activation in esophageal squamous cell carcinoma.
    Chai Y; Li Q; Zhao H; Zhang Z; Yu X; Pang L; Liu Z; Zhao J; Wang L; Li F
    Cancer Med; 2019 Nov; 8(16):7055-7064. PubMed ID: 31560173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HOXDeRNA activates a cancerous transcription program and super enhancers via genome-wide binding.
    Deforzh E; Kharel P; Zhang Y; Karelin A; El Khayari A; Ivanov P; Krichevsky AM
    Mol Cell; 2024 Oct; 84(20):3950-3966.e6. PubMed ID: 39383879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2.
    Keysar SB; Le PN; Miller B; Jackson BC; Eagles JR; Nieto C; Kim J; Tang B; Glogowska MJ; Morton JJ; Padilla-Just N; Gomez K; Warnock E; Reisinger J; Arcaroli JJ; Messersmith WA; Wakefield LM; Gao D; Tan AC; Serracino H; Vasiliou V; Roop DR; Wang XJ; Jimeno A
    J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27634934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.